The effect of intravenous ferric carboxymaltose on red cell distribution width: A subanalysis of the FAIR-HF study

Emeline M. Van Craenenbroeck, Viviane M. Conraads, Nicola Greenlaw, Giedrius Gaudesius, Claudio Mori, Piotr Ponikowski, Stefan D. Anker

Research output: Contribution to journalArticlepeer-review

Abstract

AimsRed cell distribution width (RDW), a measure of variability in red blood cell size, is a novel prognostic marker in chronic heart failure (CHF). Iron deficiency contributes to elevated RDW. In the FAIR-HF trial, i.v. ferric carboxymaltose (FCM) improved the 6 min walk test (6MWT) distance in iron-deficient CHF patients. We studied the effect of FCM on RDW and the relationship between RDW and 6MWT distance.Methods and resultsIn FAIR-HF, iron-deficient CHF patients were randomized to FCM or placebo in a 2:1 ratio. From the total cohort (n = 459), we included 415 patients in whom RDW values and 6MWT distance were available for baseline and at least one follow-up visit (after 4, 12, and 24 weeks). Baseline RDW was higher in anaemic (haemoglobin

Original languageEnglish
Pages (from-to)756-762
Number of pages7
JournalEuropean Journal of Heart Failure
Volume15
Issue number7
DOIs
Publication statusPublished - 2013

Keywords

  • Chronic heart failure
  • Exercise capacity
  • Ferric carboxymaltose
  • Iron deficiency
  • Red cell distribution width

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The effect of intravenous ferric carboxymaltose on red cell distribution width: A subanalysis of the FAIR-HF study'. Together they form a unique fingerprint.

Cite this